Citations

Clear

1820 citation(s) found for "Israel, E".

The Role of Glutamate and Blood–Brain Barrier Disruption as a Mechanistic Link between Epilepsy and Depression
Gruenbaum, Benjamin F. , Schonwald, Antonia, Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Boyko, Matthew , Zlotnik, Alexander Anatolievich

Mayo Clinic

Cells | July 22, 2024 | Volume: 13 | Issue: 14 | Pages: 1228

10.3390/cells13141228 | PMID 39056809 Get It

Epilepsy is associated with substantial neuropsychiatric impairments that persist long after the onset of the condition, significantly impacting quality of life. The goal of this review was to uncover how the pathological consequences of epilepsy, such as excessive glutamate release and a disrupted blood–brain barrier (BBB), contribute to the emergence of neuropsychiatric disorders. We hypothesize that epilepsy induces a dysfunctional BBB through hyperexcitation, which then further amplifies post-ictal glutamate levels and, thus, triggers neurodegenerative and neuropsychiatric processes. This review identifies the determinants of glutamate concentration levels in the brain and explores potential therapeutic interventions that restore BBB integrity. Our focus on therapeutic BBB restoration is guided by the premise that it may improve glutamate regulation, consequently mitigating the neurotoxicity that contributes to the onset of neuropsychiatric symptoms.
Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone
Patidar, Kavish R. , Tu, Wanzhu , Cotter, Thomas G. , Asgharpour, Amon , Jan, Muhammad Y. , Tang, Qing , Taiwo, Moyinoluwa, Nagesh, Prashanth Thevkar , Kamath, Patrick S. , Chalasani, Naga , Nagy, Laura E. , Shah, Vijay H. , Investigators, for The AlcHepNet, Vargas, Hugo E. , Duarte‐Rojo, Andrés , Simonetto, Douglas A , Thevkar Nagesh, Prashanth , Dasarathy, Srinivasan , Kamath, Patrick S , Szabo, Gyongyi , Mitchell, Mack , Mehal, Wajahat Z , Gawrieh, Samer , Sanyal, A J , Cotter, T G , Vargas, Hugo E , Duarte-Rojo, Andres , Patidar, Kavish R , Simonetto, Douglas A. , Yu, Yunpeng , Li, Yang , McClain, Craig J. , Bataller, Ramon A , Gawrieh, Samer , Sanyal, Arun J. , Investigators, for The AlcHepNet

Mayo Clinic

Hepatology | July 19, 2024 | Volume: 81 | Issue: 4 | Pages: 1256-1268

10.1097/hep.0000000000001019 | PMID 39028887 Get It

Background and Aims: In a recent trial, patients with severe alcohol-associated hepatitis treated with anakinra plus zinc (A+Z) had lower survival and higher acute kidney injury (AKI) rates versus prednisone (PRED). We characterize the clinical factors and potential mechanisms associated with AKI development in that trial. Approach and Results: Data from 147 participants in a multicenter randomized clinical trial (74 A+Z, 73 PRED) were analyzed. AKI, AKI phenotypes, and kidney injury biomarkers were compared between participants who did/did not develop AKI in the 2 treatment arms. Multivariable competing risk analyses were performed to identify baseline risk factors for incident AKI, with death treated as a competing event. Risk factors considered were age, sex, mean arterial pressure, white blood cell count, albumin, MELD, ascites, HE, and treatment arm. At baseline, no participants had AKI; 33% (n=49) developed AKI during follow-up. AKI incidence was higher in A+Z than in PRED (45% [n=33] versus 22% [n=16], p=0.001). AKI phenotypes were similar between the 2 treatment arms (p=0.361), but peak AKI severity was greater in A+Z than PRED (stage 3 n=21 [63.6%] vs. n=8 [50.0%], p=0.035). At baseline, urine-neutrophil-gelatinase–associated lipocalin levels were similar between participants who developed AKI in both treatment arms (p=0.319). However, day 7 and 14 urine-neutrophil-gelatinase–associated lipocalin levels were significantly elevated in participants treated with A+Z who developed AKI versus participants treated with PRED who developed AKI (p=0.002 and 0.032, respectively). On multivariable competing risk analysis, only A+Z was independently associated with incident AKI (subdistribution hazard ratio 2.35, p=0.005). Conclusions: AKI occurred more frequently and was more severe in participants treated with A+Z. A+Z–treated participants with AKI had higher urine-neutrophil-gelatinase–associated lipocalin, suggesting that A+Z maybe nephrotoxic in patients with severe alcohol-associated hepatitis.
Artificial intelligence in cardiac surgery: A systematic review
Sulague, Ralf Martz , Beloy, Francis Joshua , Medina, Jillian Reeze , Mortalla, Edward Daniel, Cartojano, Thea Danielle, Macapagal, Sharina , Kpodonu, Jacques

Mayo Clinic

World Journal of Surgery | July 17, 2024 | Volume: 48 | Issue: 9 | Pages: 2073-2089

10.1002/wjs.12265 | PMID 39019775 Get It

Abstract Background Artificial intelligence (AI) has emerged as a tool to potentially increase the efficiency and efficacy of cardiovascular care and improve clinical outcomes. This study aims to provide an overview of applications of AI in cardiac surgery. Methods A systematic literature search on AI applications in cardiac surgery from inception to February 2024 was conducted. Articles were then filtered based on the inclusion and exclusion criteria and the risk of bias was assessed. Key findings were then summarized. Results A total of 81 studies were found that reported on AI applications in cardiac surgery. There is a rapid rise in studies since 2020. The most popular machine learning technique was random forest ( n = 48), followed by support vector machine ( n = 33), logistic regression ( n = 32), and eXtreme Gradient Boosting ( n = 31). Most of the studies were on adult patients, conducted in China, and involved procedures such as valvular surgery (24.7%), heart transplant (9.4%), coronary revascularization (11.8%), congenital heart disease surgery (3.5%), and aortic dissection repair (2.4%). Regarding evaluation outcomes, 35 studies examined the performance, 26 studies examined clinician outcomes, and 20 studies examined patient outcomes. Conclusion AI was mainly used to predict complications following cardiac surgeries and improve clinicians' decision‐making by providing better preoperative risk assessment, stratification, and prognostication. While the application of AI in cardiac surgery has greatly progressed in the last decade, further studies need to be conducted to verify accuracy and ensure safety before use in clinical practice.
A scoping review of geriatric emergency medicine research transparency in diversity, equity, and inclusion reporting
Suh, Michelle , Ordoñez, Edgardo , Cameron, Lauren , Ahmad, Surriya, Zirulnik, Alexander , Landry, Alden , Spencer, Vivian , Obi, Tracey, Weaver, Emily H., Carpenter, Christopher R , Chary, Anita Nandkumar , Hardi, Angela , Weaver, Emily H., Carpenter, Christopher R.

Mayo Clinic

Journal of the American Geriatrics Society | July 12, 2024 | Volume: 72 | Issue: 11 | Pages: 3551-3566

10.1111/jgs.19052 | PMID 38994587 Get It

Abstract Introduction The intersection of ageism and racism is underexplored in geriatric emergency medicine (GEM) research. Methods We performed a scoping review of research published between January 2016 and December 2021. We included original emergency department‐based research focused on falls, delirium/dementia, medication safety, and elder abuse. We excluded manuscripts that did not include (1) original research data pertaining to the four core topics, (2) older adults, (3) subjects from the United States, and (4) for which full text publication could not be obtained. The primary objective was to qualitatively describe reporting about older adults' social identities in GEM research. Secondary objectives were to describe (1) the extent of inclusion of minoritized older adults in GEM research, (2) GEM research about health equity, and (3) feasible approaches to improve the status quo of GEM research reporting. Results After duplicates were removed, 3277 citations remained and 883 full‐text articles were reviewed, of which 222 met inclusion criteria. Four findings emerged. First, race and ethnicity reporting was inconsistent. Second, research rarely provided a rationale for an age threshold used to define geriatric patients. Third, GEM research more commonly reported sex than gender. Fourth, research commonly excluded older adults with cognitive impairment and speakers of non‐English primary languages. Conclusion Meaningful assessment of GEM research inclusivity is limited by inconsistent reporting of sociodemographic characteristics, specifically race and ethnicity. Reporting of sociodemographic characteristics should be standardized across different study designs. Strategies are needed to include in GEM research older adults with cognitive impairment and non‐English primary languages.
Multicenter Study on Physician-Modified Endografts for Thoracoabdominal and Complex Abdominal Aortic Aneurysm Repair
Tsilimparis, Nikolaos , Melo, Ryan Gouveia e , Scali, Salvatore T. , Mendes, Bernardo C. , Han, Sukgu M. , Schermerhorn, Marc L. , Adam, Donald J., Malas, Mahmoud B. , Starnes, Benjamin W., Branzan, Daniela , Timaran, Carlos H. , Bertoglio, Luca , Pedro, Luís Mendes , Pyun, Alyssa J., Magee, Gregory A. , Swerdlow, Nicholas J. , Juszczak, Maciej , Patel, Rohini J. , Panuccio, Giuseppe , Sweet, Matthew P. , Becquemin, J.-P. , Canonge, Jennifer , Porras-Colón, Jésus , Giordano, Antonino , Gouveia E Melo, Ryan , Tenorio, Emanuel R , Scali, Salvatore , Mendes, Bernardo, Han, Sukgu , Schermerhorn, Marc , Farber, Mark , Kolbel, Tilo , Joseph, George , Branzan, Daniela , H Timaran, Carlos , Cieri, Enrico , Verzini, Fabio , Beck, Adam W , Chait, Jesse , Pyun, Alyssa , Magee, Gregory A , Juszczak, Maciej , Barleben, Andrew R. , Patel, Rohini , Panuccio, Giuseppe , Sweet, Matthew P , Zettervall, Sara L , Becquemin, Jean-Pierre , Canonge, Jennifer , Porras-Colón, Jésus , Dias-Neto, Marina , Giordano, Antonino , Oderich, Gustavo S , Tenorio, Emanuel R. , Kölbel, Tilo , Cochennec, Frédéric , Gomes, Vivian Carla , Dias‐Neto, Marina , Oderich, Gustavo S.

Mayo Clinic

Circulation | July 11, 2024 | Volume: 150 | Issue: 17 | Pages: 1327-1342

10.1161/circulationaha.123.068587 | PMID 38989565 Get It

BACKGROUND: Physician modified endografts (PMEGs) have been widely used in the treatment of complex abdominal aortic aneurysm and thoracoabdominal aortic aneurysm, however, previous data are limited to small single center studies and robust data on safety and effectiveness of PMEGs are lacking. We aimed to perform an international multicenter study analyzing the outcomes of PMEGs in complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms. METHODS: An international multicenter single-arm cohort study was performed analyzing the outcomes of PMEGs in the treatment of elective, symptomatic, and ruptured complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms. Variables and outcomes were defined according to the Society for Vascular Surgery reporting standards. Device modification and procedure details were collected and analyzed. Efficacy outcomes included technical success and safety outcomes included major adverse events and 30-day mortality. Follow-up outcomes included reinterventions, endoleaks, target vessel patency rates and overall and aortic-related mortality. Multivariable analysis was performed aiming at identifying predictors of technical success, 30-day mortality, and major adverse events. RESULTS: Overall, 1274 patients were included in the study from 19 centers. Median age was 74 (IQR, 68–79), and 75.7% were men; 45.7% were complex abdominal aortic aneurysms, and 54.3% were thoracoabdominal aortic aneurysms; 65.5% patients presented electively, 24.6% were symptomatic, and 9.9% were ruptured. Most patients (83.1%) were submitted to a fenestrated repair, 3.6% to branched repair, and 13.4% to a combined fenestrated and branched repair. Most patients (85.8%) had ≥3 target vessels included. The overall technical success was 94% (94% in elective, 93.4% in symptomatic, and 95.1% in ruptured cases). Thirty-day mortality was 5.8% (4.1% in elective, 7.6% in symptomatic, and 12.7% in ruptured aneurysms). Major adverse events occurred in 25.2% of cases (23.1% in elective, 27.8% in symptomatic, and 30.3% in ruptured aneurysms). Median follow-up was 21 months (5.6–50.6). Freedom from reintervention was 73.8%, 61.8%, and 51.4% at 1, 3, and 5 years; primary target vessel patency was 96.9%, 93.6%, and 90.3%. Overall survival and freedom from aortic-related mortality was 82.4%/92.9%, 69.9%/91.6%, and 55.0%/89.1% at 1, 3, and 5 years. CONCLUSIONS: PMEGs were a safe and effective treatment option for elective, symptomatic, and ruptured complex aortic aneurysms. Long-term data and future prospective studies are needed for more robust and detailed analysis.
Risk of Pancreatitis After Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Pancreatic Cystic Lesions: A Systematic Review and Meta-Analysis
Magahis, Patrick T. , Chhoda, Ankit , Berzin, Tyler M. , Farrell, James J. , Wright, Drew , Rizvi, Anam, Hanscom, Mark , Carr-Locke, David L., Sampath, Kartik, Sharaiha, Reem Z. , Mahadev, SriHari , Wright, Drew N , Berzin, Tyler M , Carr‐Locke, David L.

Mayo Clinic

American Journal of Gastroenterology | July 8, 2024 | Volume: 119 | Issue: 11 | Pages: 2174-2186

10.14309/ajg.0000000000002942 | PMID 38976379 Get It

INTRODUCTION: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is frequently used to risk-stratify pancreatic cystic lesions (PCLs). Rising PCL incidence and developments in tissue acquisition and specimen analysis necessitate updated appraisal of EUS-FNA safety, particularly the risk of postprocedure pancreatitis, the most common EUS-FNA-related adverse event. Our systematic review aims to accurately quantify the risk of EUS-FNA-related pancreatitis to best inform decisions regarding EUS-FNA's optimal role in PCL workup. METHODS: We performed systematic searches in 4 databases from inception to April 2024 for original English-language studies investigating EUS-FNA-related pancreatitis. We extracted data on demographics and EUS-FNA-related pancreatitis risk, severity, and risk factors. These were meta-analyzed through the DerSimonian Laird Method using a random-effects model. Meta-regression of pancreatitis risk was performed to delineate associations with clinical and procedural characteristics. RESULTS: Sixty-four studies comprised 8,086 patients and reported 110 EUS-FNA-related pancreatitis events. Pooled risk of EUS-FNA-related pancreatitis was 1.4% (95% confidence intervals, −0.8% to 3.5%; I 2 = 0.00), which was predominantly of mild severity (67%) and uniformly nonfatal. Pancreatitis risk lacked significant association with sample size, age, sex, cyst size, needle caliber, or passes, although we noted trends toward higher risk in studies published after 2015, those using higher gauge needles (19 G vs 22 G/25 G), and those performing EUS-guided through-the-needle biopsy. DISCUSSION: We note with high certainty that pancreatitis after EUS-FNA of PCLs is infrequent and mild in severity with no mortality in the included cohort. EUS-guided through-the-needle biopsy may serve as a significant risk factor for EUS-FNA-related pancreatitis risk; however, further studies are needed to delineate other predisposing characteristics.
Targeting IL-1 controls refractory pityriasis rubra pilaris
Schmauch, Eloi , Severin, Yannik , Xing, Xianying , Mangold, Aaron R. , Conrad, Curdin , Johannsen, Pål, Kahlenberg, J. Michelle , Mellett, Mark , Navarini, Alexander A. , Nobbe, Stefan , Nilsson, Jakob , Linna-Kuosmanen, Suvi , Snijder, Berend , Contassot, Emmanuel , Kolios, Antonios G.A. , Mangold, A R , Johansen, Pål , Navarini, Alexander , Sarkar, Mrinal K , Satyam, Abhigyan , Tsoi, Lam C , French, Lars E , Nilsson, Jakob , Linna-Kuosmanen, Suvi , Kaikkonen, Minna U , Snijder, Berend , Kellis, Manolis , Gudjonsson, Johann E , Tsokos, George C. , Contassot, Emmanuel , Kolios, Antonios G A , Kahlenberg, J Michelle , Sarkar, Mrinal K. , Tsoi, Lam C.

Mayo Clinic

Science Advances | July 3, 2024 | Volume: 10 | Issue: 27 | Pages: No page available

10.1126/sciadv.ado2365 | PMID 38959302 Get It

Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease with a poorly understood pathogenesis. Through a molecularly driven precision medicine approach and an extensive mechanistic pathway analysis in PRP skin samples, compared to psoriasis, atopic dermatitis, healed PRP, and healthy controls, we identified IL-1β as a key mediator, orchestrating an NF-κB–mediated IL-1β–CCL20 axis, including activation of CARD14 and NOD2. Treatment of three patients with the IL-1 antagonists anakinra and canakinumab resulted in rapid clinical improvement and reversal of the PRP-associated molecular signature with a 50% improvement in skin lesions after 2 to 3 weeks. This transcriptional signature was consistent with in vitro stimulation of keratinocytes with IL-1β. With the central role of IL-1β underscoring its potential as a therapeutic target, our findings propose a redefinition of PRP as an autoinflammatory keratinization disorder. Further clinical trials are needed to validate the efficacy of IL-1β antagonists in PRP.
STAGER checklist: Standardized testing and assessment guidelines for evaluating generative artificial intelligence reliability
Chen, Jinghong , Zhu, Lingxuan , Zeng, Dongqiang , Qi, Chang , Tang, Bufu , Shi, Wenjie , Guo, Shipeng, Sun, Xu , Ngo, Trunghieu, Pu, Zhongji , He, Yongbin, Wu, Haiyang , Cheungpasitporn, Wisit, Huang, Haojie , Wang, Shixiang , Cabannes, Loïc, Ren, Gerald Sng Gui , Ali, Stephen R , Cheng, Quan, Miao, Kai , Mou, Weiming , Lin, Anqi , Zeng, Dongqiang, Liu, Zaoqu , Jiang, Aimin , Shi, Wenjie, Kahlert, Ulf D. , Zhou, Jian‐Guo , Lu, Xiaofan , Jia, Baolei , Jeon, Che Ok , Gu, Shuqin , Cheungpasitporn, Wisit , Mao, Weipu , Chen, Xin , Cabannes, Loïc, Whitaker, Iain Stuart , Cheng, Quan, Yuan, Shuofeng , Luo, Peng

Mayo Clinic

iMetaOmics | July 2, 2024 | Volume: 1 | Issue: 1 | Pages: No page available

10.1002/imo2.7 | PMID 41675544 Get It

Abstract Generative artificial intelligence (AI) holds immense potential for medical applications, but the lack of a comprehensive evaluation framework and methodological deficiencies in existing studies hinder its effective implementation. Standardized assessment guidelines are crucial for ensuring reliable and consistent evaluation of generative AI in healthcare. Our objective is to develop robust, standardized guidelines tailored for evaluating generative AI performance in medical contexts. Through a rigorous literature review utilizing the Web of Sciences, Cochrane Library, PubMed, and Google Scholar, we focused on research testing generative AI capabilities in medicine. Our multidisciplinary team of experts conducted discussion sessions to develop a comprehensive 32‐item checklist. This checklist encompasses critical evaluation aspects of generative AI in medical applications, addressing key dimensions such as question collection, querying methodologies, and assessment techniques. The checklist and its broader assessment framework provide a holistic evaluation of AI systems, delineating a clear pathway from question gathering to result assessment. It guides researchers through potential challenges and pitfalls, enhancing research quality and reporting and aiding the evolution of generative AI in medicine and life sciences. Our framework furnishes a standardized, systematic approach for testing generative AI's applicability in medicine. For a concise checklist, please refer to Table S or visit GenAIMed.org .
Echocardiogram Vector Embeddings Via R3D Transformer for the Improvement of Ejection Fraction Estimation Instruments
Lee, Somin Mindy , Chung, Daniel, Kaker, Vasu, Zhao, Yongyi, Perera, Sudheesha , Sasankan, Prabhu, Tang, George, Kpodonu, Jacques , Kazzi, Brigitte , Chung, Daniel J, Riaz, Irbaz Bin , Tang, George, Kuo, Po‐Chih , Celi, Leo Anthony

Mayo Clinic

2024 IEEE International Instrumentation and Measurement Technology Conference (I2MTC) | June 28, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-6

10.1109/i2mtc60896.2024.10561175 Get It

Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU)
Solomon, Scott R. , Arnason, Jon , Johnston, Patrick B. , Glaß, Bertram , Mutsaers, Pim , Hernandez‐Ilizaliturri, Francisco J. , Lunning, Matthew A. , Chow, Victor A. , Santamaria, Josu, Colicino, Silvia , Stepan, Lara , Kamdar, Manali , Bachanová, Veronika , Ibrahimi, Sami , Mielke, Stephan , Izutsu, Koji , Morschhauser, Franck , Ogasawara, Ken , Abramson, Jeremy S.

Mayo Clinic

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 7013-7013

10.1200/jco.2024.42.16_suppl.7013 Get It

7013 Background: Liso-cel is an autologous, CD19-directed, 4-1BB CAR T cell product. In prespecified interim and primary analyses of TRANSFORM (NCT03575351), liso-cel showed significant improvements in efficacy vs SOC in pts with R/R LBCL. Here we report results after ~3-y FU. Methods: TRANSFORM is a randomized phase 3 study comparing liso-cel vs SOC (CT [R-DHAP, R-ICE, or R-GDP] then high-dose CT [HDCT] + ASCT) in adults aged ≤ 75 y with LBCL primary refractory to or relapsed ≤ 12 mo after first-line therapy and eligible for ASCT. Liso-cel arm pts underwent lymphodepletion followed by liso-cel (100 × 10 6 CAR + T cells). Bridging therapy was allowed. SOC arm pts received 3 cycles of CT; responding pts proceeded to HDCT + ASCT. Crossover to receive liso-cel was allowed for SOC arm pts if criteria were met. The primary endpoint was event-free survival (EFS) per independent review committee (IRC). Key secondary endpoints included CR rate and PFS per IRC, and OS. Endpoints were not statistically retested and are reported descriptively. Results: In total, 184 pts were randomized (92 per arm); baseline characteristics were reported (Abramson et al. Blood 2023). Median (range) FU was 33.9 mo (0.9–53.0). Median EFS, PFS, and duration of response (DOR) were longer for liso-cel vs SOC, similar to the primary analysis (Table). A total of 61 (66%) SOC arm pts crossed over to receive liso-cel. Median OS was not reached (NR) in either arm; 36-mo OS rates were numerically higher for liso-cel. Of 76 total deaths (liso-cel, n = 34; SOC, n = 42 [crossover pts, n = 33]), 10 occurred since the primary analysis (liso-cel, n = 6; SOC, n = 4 [all crossover pts]); most were due to disease progression or complications (n = 6). Safety results were consistent with the primary analysis. Cellular kinetics and B-cell aplasia will be presented. Conclusions: After median FU of 33.9 mo, liso-cel as 2L treatment in pts with primary refractory or early relapsed LBCL resulted in deepening of response and continued improvement in efficacy endpoints over SOC, confirming the ongoing benefit of liso-cel. Clinical trial information: NCT03575351 . [Table: see text]